Travere Therapeutics, Inc. today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its ...
Guggenheim analyst Vamil Divan reiterated a Buy rating on Savara yesterday and set a price target of $11.00. The company’s shares closed yesterday at $5.08. Claim 55% Off TipRan ...
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and ...
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...
Quanterix Corporation , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO" ...
New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bankrate on MSN
What to do if your Social Security payment is late
According to the Social Security Administration (SSA), nearly 70 million Americans received Social Security benefits in July ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results